Statins for Smith-Lemli-Opitz syndrome

Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter

doi:10.1002/14651858.cd013521

Statins for Smith-Lemli-Opitz syndrome

Cochrane Database Syst Rev. 2020;2020(1):CD013521. doi: 10.1002/14651858.cd013521.

Authors

Rami A Ballout¹, Simona Bianconi², Alicia Livinski³, Yi-Ping Fu⁴, Alan T Remaley⁵, Forbes D Porter⁶

Affiliations

¹ Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA.
² National Institute of Child Health and Development, NIH, Bethesda, USA.
³ Division of Library Services, National Institutes of Health Library, Office of Research Services, Bethesda, Maryland, USA.
⁴ Office of Biostatistics Research, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA.
⁵ Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, USA.
⁶ Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: 1. To evaluate the efficacy of statin therapy in reducing the frequency or severity of the neurobehavioral abnormalities seen in people with SLOS (e.g. aggression, anxiety, irritability, self-mutilation, autistic behaviors, sleep disturbances, etc.) (Wassif 2017). 2. To evaluate the potential effects of statin therapy on survival.

Grants and funding

Z99 HL999999/ImNIH/Intramural NIH HHS/United States